TITLE

Rapid Decline of Influenza Vaccine—Induced Antibody in the Elderly Is It Real, or Is It Relevant?

AUTHOR(S)
Skowronski, Danuta M.; Tweed, S. Aleina; De Serres, Gaston
PUB. DATE
February 2008
SOURCE
Journal of Infectious Diseases;2/15/2008, Vol. 197 Issue 4, p490
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Advisory committees have cautioned that influenza vaccine-induced antibody declines more rapidly in the elderly, falling below seroprotective levels within 4 months. We conducted a literature review to assess this assertion. The articles that were included in this review reported antibody levels ≥4 months after influenza immunization in persons ≥60 years old, interpretable in the context of annual influenza vaccine-approval criteria (seroprotection/seroconversion) specified by the Committee for Proprietary Medicinal Products (CPMP) for the elderly. The final review included 14 studies; 8 of which reported seroprotection rates. Seroprotection exceeding CPMP criteria was maintained ≥4 months after influenza immunization in all 8 of the studies reporting this for the H3N2 component and in 5 of the 7 studies reporting this for the H1N1 and B components. In determining whether CPMP criteria were met at season's end, primary antibody response appeared to be more relevant than secondary antibody decline. Both studies reporting seroprotection rates that failed CPMP criteria ≥4 months after influenza immunization for each of the H1N1 and B components had also reported failed seroprotection at 1 month after immunization. If initially achieved after immunization, seroprotection rates of 70%-100% were maintained not just at 4 months (2 studies) but also at 5 months (2 studies) and even at >6 months (4 studies), for the H3N2 and H1N1 vaccine components. Seroprotection rates appeared less consistent for the B vaccine component, throughout the postimmunization period. Seroconversion appears to vary substantially and inversely with preimmunization titers but not with age. In 2 of 6 studies reporting seroconversion alone, CPMP criteria were still met at 4 months. In the other 4 studies, the main reason for failure at 4 months was primary failure at 1 month. A total of 6 studies compared antibody persistence by age, and no consistent differences were found on that basis. The historic concern that the influenza vaccine-induced antibody response in the elderly declines more rapidly and below seroprotective levels within 4 months of immunization should be reconsidered.
ACCESSION #
31472903

 

Related Articles

  • Study: Flu vaccines aren't always helpful in shielding elderly from bug.  // Journal of Business (10756124);10/13/2005, Vol. 20 Issue 21, pB2 

    Discusses a study which focused on the efficacy of vaccine against influenza on older people. Findings of the study that the vaccines are only modestly effective for elderly people in long-term care facilities; Detection of less efficacy of the vaccine in older people in the general community;...

  • Universal flu vaccination may be on the horizon.  // GP: General Practitioner;2/27/2009, p8 

    The article reports that recent research by Dr Wayne Marasco and his team from Harvard Medical School, have revealed that universal vaccination against current and future influenza outbreaks could be possible following the development of antibodies that can bind to multiple strains of the virus....

  • Influenza vaccination among the elderly Spanish population: trend from 1993 to 2003 and vaccination-related factors. De Andres, Ana Lopez; Garrido, Pilar Carrasco; Hernández-Barrera, Valentin; Del Pozo, Silvia Vázquez-Fernández; De Miguel, Angel Gil; Jiménez-García, Rodrigo // European Journal of Public Health;Jun2007, Vol. 17 Issue 3, p272 

    Background: Influenza is an important public health problem that particularly affects elderly subjects and influenza vaccination is a safe, effective and efficient method for prevention of influenza-related complications in elderly individuals with or without underlying chronic conditions. This...

  • Frequency of Adverse Reactions to Influenza Vaccine in the Elderly. Margolis, Karen L.; Nichol, Kristin L.; Poland, Gregory A.; Pluhar, Robert E. // JAMA: Journal of the American Medical Association;9/5/90, Vol. 264 Issue 9, p1139 

    Details a study which compared the frequency of adverse reactions following administration of 1988-1989 trivalent split-antigen influenza vaccine and saline placebo among the elderly in the U.S. Data from outpatient veterans; Post-injection symptoms; Safety of administering influenza vaccine.

  • Flu jabs halve mortality.  // GP: General Practitioner;10/5/2007, p66 

    The article reports on a research, which has stated that vaccinating the elderly against flu can almost halve the risk of death. It was based on data collected from 18 cohort studies carried out between 1990-2000 by researchers in the U.S. Influenza vaccination was found to reduce the risk of...

  • Vaccines for Preventing Influenza in Older Patients. Guirguis-Blake, Janelle // American Family Physician;2/1/2007, Vol. 75 Issue 3, p337 

    The article discusses the efficacy of influenza vaccines in older patients. Based on observational studies, influenza vaccination in older people reduces pneumonia cases, hospital admissions and influenza-related deaths by 45%. Influenza vaccination also prevents hospitalizations from the...

  • Reports of Expired Live Attenuated Influenza Vaccine Being Administered -- United States, 2007-2014. Haber, Penina; Schembri, Christopher P.; Lewis, Paige; Hibbs, Beth; Shimabukuro, Tom // MMWR: Morbidity & Mortality Weekly Report;9/5/2014, Vol. 63 Issue 35, p773 

    The article presents information on reports of expired live attenuated influenza vaccine (LAIV) administered between 2007-2014 in the U.S. There are two types of vaccine that are approved in the U.S. including injectable inactivated influenza vaccine (IIV) and LAIV. According to a report, from...

  • Influenza Vaccine May Reduce Risk of Death Among the Elderly. Merriman, John // Pulmonary Reviews;Nov2007, Vol. 12 Issue 11, p12 

    The article discusses research being done on the efficacy of influenza vaccine in the community-dwelling elderly. It references a study by Kristin L. Nichol and colleagues published in the October 4, 2007 issue of the "New England Journal of Medicine." Key findings suggest that influence vaccine...

  • Influenza Vaccination and Self-Reported Reasons for Not Receiving Influenza Vaccination Among Medicare Beneficiaries Aged ≥65 years -- United States, 1991-2002.  // MMWR: Morbidity & Mortality Weekly Report;11/5/2004, Vol. 53 Issue 43, p1012 

    Presents the results of the Medicare Current Beneficiary Survey (MCBS) conducted by the U.S. Centers for Medicare & Medicaid Services to measure the annual influenza vaccination rates among the U.S. elderly population from 1991-2002. Reasons frequently cited by the elderly people for not...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics